title: Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy.
abstract: BACKGROUND
  Atomoxetine is FDA-approved as a treatment of attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years to adult. Among pediatric clinical trials of atomoxetine to date, six with a randomized, double-blind, placebo-controlled design were used in this meta-analysis. The purpose of this article is to describe and compare the treatment response and tolerability of atomoxetine between younger children (6-7 years) and older children (8-12 years) with ADHD, as reported in these six acute treatment trials.
  
  
  METHODS
  Data from six clinical trials of 6-9 weeks duration were pooled, yielding 280 subjects, ages 6-7 years, and 860 subjects, ages 8-12 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)-diagnosed ADHD. Efficacy was analyzed using the ADHD Rating Scale-IV (ADHD-RS), Conners' Parent Rating Scale-revised (CPRS-R:S), and the Clinical Global Impression of ADHD Severity (CGI-ADHD-S).
  
  
  RESULTS
  Atomoxetine was superior to placebo in both age categories for mean (SD) change in ADHD-RS total, total T, and subscale scores; 3 CPRS-R:S subscales; and CGI-ADHD-S from baseline. Although there were no significant treatment differentials between the age groups for these efficacy measures, the age groups themselves, regardless of treatment, were significantly different for ADHD-RS total (younger: ATX = -14.2 [13.8], PBO = -4.6 [10.4]; older: ATX = -15.4 [13.2], PBO = -7.3 [12.0]; p = .001), total T (younger: ATX = -15.2 [14.8], PBO = -4.9 [11.2]; older: ATX = -16.4 [14.6], PBO = -7.9 [13.1]; p = .003), and subscale scores (Inattentive: younger: ATX = -7.2 [7.5], PBO = -2.4 [5.7]; older: ATX = -8.0 [7.4], PBO = -3.9 [6.7]; p = .043; Hyperactive/Impulsive: younger: ATX = -7.0 [7.2], PBO = -2.1 [5.4]; older: ATX = -7.3 [7.0], PBO = -3.4 [6.3]; p < .001), as well as the CGI-ADHD-S score (younger: ATX = -1.2 [1.3], PBO = -0.5 [0.9]; older: ATX = -1.4 [1.3], PBO = -0.7 [1.1]; p = .010). Although few subjects discontinued from either age group due to adverse events, a significant treatment-by-age-group interaction was observed for abdominal pain (younger: ATX = 19%, PBO = 6%; older: ATX = 15%, PBO = 13%; p = .044), vomiting (younger: ATX = 14%, PBO = 2%; older: ATX = 9%, PBO = 6%; p = .053), cough (younger: ATX = 10%, PBO = 6%; older: ATX = 3%, PBO = 9%; p = .007), and pyrexia (younger: ATX = 5%, PBO = 2%; older: ATX = 3%, PBO = 5%; p = .058).
  
  
  CONCLUSIONS
  Atomoxetine is an effective and generally well-tolerated treatment of ADHD in both younger and older children as assessed by three recognized measures of symptoms in six controlled clinical trials.
  
  
  BACKGROUND
  Not Applicable.
authors.affiliation: University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE 68198-5581, USA. ckratoch@unmc.edu
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Kratochvil
authors.forename: Denái R
authors.initials: DR
authors.lastname: Milton
authors.forename: Brigette S
authors.initials: BS
authors.lastname: Vaughan
authors.forename: Laurence L
authors.initials: LL
authors.lastname: Greenhill
references.citation: J Am Acad Child Adolesc Psychiatry. 2006 Aug;45(8):919-927
references.pmid: 16865034
references.citation: J Am Acad Child Adolesc Psychiatry. 1998 Jul;37(7):695-702
references.pmid: 9666624
references.citation: J Am Acad Child Adolesc Psychiatry. 2001 May;40(5):508-15
references.pmid: 11349694
references.citation: Arch Gen Psychiatry. 1999 Dec;56(12):1073-86
references.pmid: 10591283
references.citation: J Am Acad Child Adolesc Psychiatry. 2006 Feb;45(2):149-157
references.pmid: 16429085
references.citation: J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1284-1293
references.pmid: 17023867
references.citation: J Am Acad Child Adolesc Psychiatry. 1996 Feb;35(2):204-14
references.pmid: 8720630
references.citation: Am J Psychiatry. 2002 Nov;159(11):1896-901
references.pmid: 12411225
references.citation: J Clin Psychiatry. 2002 Dec;63(12):1140-7
references.pmid: 12523874
references.citation: Pediatrics. 2004 Jul;114(1):e1-8
references.pmid: 15231966
references.citation: Cardiovasc Res. 1997 Jul;35(1):2-3
references.pmid: 9302340
references.citation: J Abnorm Child Psychol. 1998 Dec;26(6):475-94
references.pmid: 9915654
references.citation: J Clin Psychiatry. 2002;63 Suppl 12:44-9
references.pmid: 12562061
references.citation: Am J Psychiatry. 2008 Jun;165(6):721-30
references.pmid: 18281409
references.citation: J Child Adolesc Psychopharmacol. 2007 Apr;17(2):175-85
references.pmid: 17489712
references.citation: J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894-921
references.pmid: 17581453